Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (PaTK02)

• ClinicalTrials.gov Identifier: NCT02446093
• Recruitment Status: Recruiting
• First Posted: May 18, 2015
• Last Update Posted: December 9, 2022
• Sponsor: Candel Therapeutics, Inc.
• Collaborator: Mayo Clinic
• Information provided by (Responsible Party): Candel Therapeutics, Inc.

Study Description

Brief Summary:

The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being treated with neoadjuvant chemoradiation (CR) or stereotactic body radiation therapy (SBRT). The Standard of Care (SOC) Control arm will be used as a benchmark for informal comparisons of efficacy, safety, and biomarkers.

Condition or disease	Intervention/treatment	Phase
Borderline Resectable Pancreatic Adenocarcinoma	Biological: Aglatimagene besadenovec; Radiation: Chemoradiation; Radiation: Stereotactic body radiation therapy; Procedure: Surgery	Phase 2

Detailed Description:

Study design is an open-label Phase 2 trial that randomizes subjects with borderline resectable pancreatic adenocarcinoma to received SOC with (Test arm) or without (Control arm) the addition of CAN-2409 + prodrug (2:1 randomization, Test: Control), beginning after completion of at least 4 months (8 cycles) of a FOLFIRINOX based induction therapy. Confirmation of borderline resectable status will be based on central radiologic review following completion of FOLFIRINOX based induction regimen. Upon enrollment, eligible subjects will receive three courses of CAN-2409 + prodrug, the first course starting prior to CR or SBRT, the second course concurrent with CR or just following completion of SBRT, and the third at time of resection. Up to 2 additional courses are allowed at the time of disease recurrence.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 54 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Neoadjuvant CAN-2409 Plus Prodrug in Combination With Chemoradiation or Stereotactic Body Radiation Therapy for Borderline Resectable Pancreatic Adenocarcinoma
• Study Start Date: October 2015
• Estimated Primary Completion Date: December 2025
• Estimated Study Completion Date: July 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Test Arm; CAN-2409 + prodrug (valacylovir or acyclovir) in combination with neoadjuvant chemoradiation or SBRT + Surgery	Biological: Aglatimagene besadenovec; Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.; Other Names: CAN-2409; AdV-tk; Radiation: Chemoradiation; CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.; Radiation: Stereotactic body radiation therapy; SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.; Procedure: Surgery; Surgical resection should be performed within 8 weeks after completing CR or SBRT.
Active Comparator: Control Arm; Neoadjuvant chemoradiation or SBRT + Surgery	Radiation: Chemoradiation; CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.; Radiation: Stereotactic body radiation therapy; SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.; Procedure: Surgery; Surgical resection should be performed within 8 weeks after completing CR or SBRT.

Outcome Measures

Primary Outcome Measures :

1. Safety grade by CTCAE version 4.0 [ Time Frame: From the time of CAN-2409 administration to 30 days after the last dose of valacyclovir. ]
   Frequency of adverse events.
2. Survival Rate [ Time Frame: 24 months ]
   All eligible subjects will be followed for at least 2 additional years from the completion of primary treatment window.

Secondary Outcome Measures :

1. Overall survival (OS) from time of diagnosis [ Time Frame: 60 months ]
   Time from diagnosis until death from any cause.
2. Overall survival (OS) from time of study enrollment [ Time Frame: 60 months ]
   Time from enrollment until death from any cause.
3. Progression free survival (PFS) from time of diagnosis [ Time Frame: 60 months ]
   Time from diagnosis until first objective documentation of progression (local or distant) or death from any cause.
4. Progression free survival (PFS) from time of study enrollment [ Time Frame: 60 months ]
   Time from study enrollment to documented disease progression or death from any cause.
5. Resection rate [ Time Frame: 12 weeks ]
   Subjects will be considered to have R0 resection if all lesions are removed with negative microscopic surgical margins. Subjects will be considered to have R1 resection if all lesions are removed with any positive microscopic surgical margins.
6. Disease free survival (DFS) in subjects with R0 resection [ Time Frame: 60 months ]
   Disease-free survival (DFS) will be measured from R0 resection until first objective documentation of recurrence or death from any cause.
7. Immunological biomarker characterization in tumor and peripheral blood [ Time Frame: 24 months ]
   Immunophenotyping in the blood and in the tissue.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Pathological diagnosis of pancreatic adenocarcinoma adequately treated with a FOLFIRINOX based induction chemotherapy for at least 4 months such that they are a candidate for localized therapy with CR or SBRT followed by surgery with or without major vascular resection.
2. Subjects must be deemed to be in adequate health to undergo major surgery (e.g., pancreaticoduodenectomy).

3. Tumor accessible for injection by EUS or CT-guidance, considered potentially resectable at time of diagnosis, and classified as borderline resectable based on central radiologic review of CT scans performed following completion of FOLFIRINOX based induction chemotherapy. Resection may include major vascular resection with reconstruction as needed.

   Criteria for borderline resectable disease status:

   • No distant metastasis or lymph node involvement outside the planned resection field.
   • Venous involvement of the superior mesenteric vein (SMV) or portal view (PV) with distortion or narrowing of the vein or occlusion of the vein with suitable vessel proximal and distal, allowing for safe resection and replacement
   • Gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct tumor abutment of the hepatic artery, without extension to the celiac axis
   • Tumor abutment of the superior mesenteric artery (SMA) not to exceed > 180 degrees of the circumference of the vessel wall
4. Age > 18 years at the time of consent
5. Performance status ECOG 0 or 1
6. SGOT (AST) <3x upper limit normal

7. Total bilirubin <2mg/dl

   • Subjects with biliary obstruction can be enrolled if AST and bilirubin do not meet criteria but must meet the criteria after stenting before starting treatment
8. Creatinine <2mg/dl
9. Calculated creatinine clearance > 30ml/min
10. WBC > 3000/mm^3
11. Absolute neutrophil count (ANC) > 1000/mm^3
12. Platelets > 100,000/mm^3
13. Hemoglobin > 9g/dl
14. Signed, written informed consent

Exclusion Criteria:

1. Primary hepatic dysfunction including known cirrhosis or active hepatitis. Subjects with biliary obstruction must be stented prior to initiating treatment
2. Evidence of clinically significant pancreatitis as determined by the investigator
3. Evidence of significant ascites as determined by investigator
4. Subjects on systemic corticosteroid (>10 mg prednisone per day or equivalent), systemic immunomodulators, or other systemic immunosuppressive drugs
5. Known to be HIV+
6. Pregnant or breast-feeding. Female subjects of childbearing age must have negative serum or urine pregnancy test within 2 weeks of beginning protocol therapy
7. Other current malignancy (except squamous or basal cell skill cancers)
8. Other serious co-morbid illnesses or compromised organ function
9. Known sensitivity or allergic reactions to acyclovir or valacyclovir

Contacts and Locations

Contacts

Contact: Garrett Nichols, MD, MS; (617)916-5445; gnichols@candeltx.com

Contact: Andrea Manzanera, MD, MPH; (617)916-5445; andrea@Candeltx.com

Locations

United States, Florida

Lee Health/Regional Cancer Center; Active, not recruiting

Fort Myers, Florida, United States, 33905

Mayo Clinic; Not yet recruiting

Jacksonville, Florida, United States, 32224

Contact: Kristin East East.Kristen@mayo.edu

Principal Investigator: John Stauffer, MD

AdventHealth; Not yet recruiting

Orlando, Florida, United States, 32803

Contact: Rebecca Iorio, MS Rebecca.Iorio@AventHealth.com

Principal Investigator: Mohamedtaki Tejani, MD

Moffitt Cancer Center; Not yet recruiting

Tampa, Florida, United States, 33612

Contact: Erin Scott erin.scott@moffitt.org

Principal Investigator: Dae Won Kim, MD

Sub-Investigator: Jason Fleming, MD

Sub-Investigator: Sarah Hoffe, MD

United States, Minnesota

Mayo Clinic; Not yet recruiting

Rochester, Minnesota, United States, 55906

Contact: Lisa Seymour Seymour.Lisa@mayo.edu

Principal Investigator: Susanne Warner, MD

United States, Ohio

Ohio State University; Active, not recruiting

Columbus, Ohio, United States, 43210

United States, Virginia

University of Virginia; Recruiting

Charlottesville, Virginia, United States, 22903

Contact: Sallie Mannen 434-297-5724 sbm8qz@virginia.edu

Principal Investigator: Tri M Le, MD

Mexico

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; Active, not recruiting

Mexico City, Mexico, 14080

Sponsors and Collaborators

Candel Therapeutics, Inc.

Mayo Clinic

More Information

• Responsible Party: Candel Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT02446093
• Other Study ID Numbers: PaTK02
• First Posted: May 18, 2015
• Last Update Posted: December 9, 2022
• Last Verified: December 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Candel Therapeutics, Inc.:

Borderline resectable pancreatic adenocarcinoma; Immunotherapy; Aglatimagene besadenovec; Neoadjuvant; CAN-2409

Additional relevant MeSH terms:

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms